natgillin/translations-raw huggingface dataset:
Form I of claim 1 for use in treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of said Form I. 
Oblik I iz zahtjeva 1 za upotrebu u liječenju cistične fibroze kod sisavaca koja sadrži davanje učinkovite količine navedenog Oblika I sisavcu.
A method as claimed in Claim 16, wherein the amount of base added is at least sufficient to neutralise at least 90% of the carboxylic acid groups in the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, pri čemu je dodana količina baze najmanje dovoljna da neutralizira bar 90% skupina karboksilne kiseline u polimeru polikarboksilne kiseline.
R is methyl, phenyl, 4-hydroxy-phenyl or 4-methoxyphenyl and pharmaceutically salts, tautomers and stereoisomers thereof, characterised in that a compound of the formula II 
R je metil, fenil, 4-hidroksi-feml ili 4-metoksifenil i njihovih farmaceutskih soli, tautomera i stereoizomera, naznačeno time što spoj formule II OK
DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION 
Datum podnošenja europske prijave patenta:
The surgical cassette of claim 1, wherein the at least two pump segments are configured to be angularly positioned relative to the single roller head (203) when the at least two pump segments (103) engage the single roller head. 
Kirurška kazeta prema zahtjevu 1, naznačena time, da su najmanje dva segmenta sisaljke oblikovana da imaju kutni položaj u odnosu na jedinstvenu glavu (203) valjka kada najmanje dva segmenta (103) zahvate jedinstvenu glavu valjka.
Agents in the class also facilitate the regulation of fatty acid metabolism. Examples of PPAR-Y agonists include rosiglitazone, pioglitazone, tesaglitazar, netoglitazone, GW-409544, GW-501516 and PPAR-Y agonists known in the art. 
Sredstva u toj skupini također olakšavaju regulaciju metabolizma masnih kiselina primjeri agonista PPAR-y uključuju rosiglitazon, pioglitazon, tesaglitazar, netoglitazon, GW-409544, GW-501516 i PPAR-y agoniste poznate u struci.
Multi-purpose motor vehicle for re-establishment of safe and practicable road conditions, after car accidents, through cleaning of the road platform, according to claim 1, further comprising: 
Višenamjensko motorno vozilo (100) za ponovno uspostavljanje sigurnih i prohodnih uvjeta na cesti nakon automobilskih nezgoda, čišćenjem cestovne plohe, prema jednom ili više prethodnih patentnih zahtjeva, naznačeno time, da nadalje sadrži:
The container according to claim 1, wherein a support prop (15) extends between the flat carrying section (6) and at least one edge (7). 
Spremnik u skladu s patentnim zahtjevom 3 ili 4, naznačen time što nosač (15) se pruža između ravnog nosećeg dijela (6) i svakog ruba (7).
An enantiomerically pure compound of formula 1 wherein: . 
Enantiomerno čisti spoj formule 1 [image] naznačen time što:
A method according to claim 14, in which after the pressure impregnating of the heated wood in the impregnating chamber, hot saturated vapour is conveyed for removing the wood preservative from the surface layers of wood. A method comprising: 
Postupak sukladno bilo kojem od Zahtjeva 4-7, naznačen time što je nakon faze pritiska u impregnacijsku komoru (1) prenesena vruća zasićena para za uklanjanje konzervansa za drvo s površinskih slojeva drveta.
The reaction was quenched with 1N HCl (40 mL) and extracted with ethyl acetate (3X). 
Reakcija se prekine s IN HCI (40 mL) i ekstrahira etil acetatom (3x).
The method of any one of claims 1 to 4, wherein each of the impact functions used in step (1b) further depends on: encoding or network technical characteristics, for example the bit rate, the frame rate, the percentage of packet-loss, or the proportion of loss in a GOP or scene; and/or 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što svaka od funkcija utjecaja upotrijebljenih u koraku (1b) daljnje ovisi o: kodiranju ili tehničkim karakteristikama mreže, primjerice brzini bitova, brzini kadrova, postotku gubitka paketa, ili udjelu gubitka u GOP-u ili sceni; i/ili koeficijentima povezanim s funkcijom utjecaja.
The receiver according to claim 1 characterised in that the receiver includes a handle (22) and a spout (20) for easy disposing of the contents. 
Prijemna posuda sukladno patentnom zahtjevu 1 naznačeno time što ta prijemna posuda sadrži dršku (22) 1 grlić (20) za lako odlaganje sadržaja.
The medicine for use in accordance with the invention is preferably produced for intravenous, intra-arterial, intramuscular, intravascular, intraperitoneal or subcutaneous administration. 
Rekombinantni polipeptid ACE2 namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je stanje koje treba liječiti 1li spriječiti plućna hipertenzija.
In the example shown, the portion of supporting bracket 11 engaging the central through groove 8 b in the central leg of flat plate 8 has a projecting stop appendix 11 a, which projects towards longitudinal blade 4, to form a groove enclosing the central leg of flat plate 8, and which establishes a predetermined maximum angle of oscillation of flat plate 8, i.e. scraper 8, with respect to the travelling direction da of longitudinal blade 4; which travelling direction da is locally tangent to the cylindrical reference surface of mixing member 1 . With reference to FIGS. 
U prikazanom primjeru, dio potporne konzole 11, koja zahvaća centralni prorez 8b u centralnoj nožici ravne ploče 8, ima stršeći zaustavni dodatak 11a, koji strši prema uzdužnoj lopatici 4, da formira utor koji okružuje centralnu nožicu ravne ploče 8, 1 koji stvara predodređeni maksimalni kut oscilacije ravne ploče 8, t.j. strugača 8, s obzirom na smjer kretanja d, uzdužne lopatice 4; koji je smjer kretanja d, lokalno tangencijalan na cilindričnu referentnu plohu članka za miješanje 1.
Thus, the administration according to the invention is more concerned with reducing exposure to potentially toxic chemicals than with overcoming ectoparasite resistance to sea lice treatments. Thus viewed from one aspect the invention provides a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons, in particular sea lice, which method comprises topically exposing farmed fish, especially fish in cages, to a first and a second sea lice treatment agent, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin. 
HR P20130233 T1 PATENTNI ZAHTJEVI u Organofosfat ili karbamat za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima s tvrdim vanjskim skeletom (egzoskelet), taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
The use of any one of claims 47 to 49, wherein the composition is a dosage form of the composition according to any one of claims 23 to 30. Use of a composition according to claim 1 for the manufacture of a medicament for the treatment or prevention of a condition ameliorated by increasing a blood GLP-1 level, wherein the condition ameliorated by increasing a blood GLP-1 level is selected from the group consisting of diabetes, a condition related to diabetes, myocardial infarction, learning impairment, memory impairment, and a neurodegenerative disorder; or wherein the condition ameliorated by increasing a blood GLP-1 level is a neurodegenerative disorder selected from the group consisting of excitotoxic brain damage caused by severe epileptic seizures, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion-associated disease, stroke, motor-neuron disease, learning or memory impairment, traumatic brain injury, spinal cord injury, and peripheral neuropathy. 
Uporaba pripravka u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje ili prevenciju stanja koja se poboljšavaju povećanjem nivoa GLP-1 u krvi, pri čemu je stanje koje se može poboljšati povećanjem nivoa GLP-1 u krvi izabrano iz skupine koju čine dijabetes, stanje povezano s dijabetesom, srčani infarkt, smanjeno pamćenje, smanjeno učenje i neurodegenerativni poremećaj; ili pri čemu je stanje koje se može poboljšati povećanjem nivoa GLP-1 u krvi je neurodegenerativni poremećaj izabran iz skupine koju čine ekscitoksično oštećenje mozga uzrokovano jakim epileptičkim događajima, Alzheimer-ova bolest, Parkinson-ova bolest, Huntington-ova bolest, bolest povezana s prionom, udar, motoričko-neuronska bolest, smanjeno učenje ili pamćenje, traumatsko oštećenje mozga, oštećenje leđne moždine i periferna neuropatija.
determining the dilution with the highest dilution factor capable of inhibiting the growth of the microorganism; 
određivanje razrjeđenja s najvišim faktorom razrjeđenja koji može inhibirati rast mikroorganizma;
Composition according to clam 1 or 2, comprising cytisine having average particle size d50 in the range from 10 µm to 30 µm. 
Sastav prema zahtjevu 1, obuhvaćajući citizin koji ima prosječnu veličinu čestice dsg u rasponu od 10 um do 30 um.
The method according to one of claims 9 to 13, characterized in that it comprises a fractionating step followed by an enzymatic treatment step, prior to the refining. 
Postupak prema jednom od zahtjeva 9 do 13, naznačen time što obuhvaća korak frakcioniranja nakon kojeg slijedi korak enzimske obrade, prije rafiniranja.
Figure 1A is a sectional view of the embodiment of Figure 1, taken along lines 1A-1A in Figure 1; 
SI. 1A je presjek realizacije sa sl. 1, uzet duž linije 1A-IA sa sl. 1,
The residue was purified by reverse phase HPLC (Gilson) to give the title compound (4.9 mg). 
Ostatak se pročisti obrnuto faznom HPLC (Gilson) da bi se dobio naslovni spoj (4.9 mg).
pegylating the AvPAL variant by mixing polyethylene glycol with the AvPAL variant; 
pegiliranju varijante AvPAL miješanjem polietilen-glikola s varijantom AvPAL;
The push stick according to claim 1, wherein the detection device has an electro-optical or electro-acoustic scanning device which detects whether the push surface and the holding-down surface lie flat against the workpiece. 
Potiskivač u skladu s patentnim zahtjevom 1, 2 ili 3, naznačena time što detekcijski uređaj ima uređaj za elektrooptičko ili elektroakustičko skeniranje, koji detektira leže li potisna površina i pritisna površina ravno na predmetu obrade.
The use according to claim 8, wherein the infusion time for intravenous injection is 1-2 hours for said effective therapeutic amount of PLD and about 3:hours for said effective therapeutic amount of ET-743. 
Primjena prema patentnom zahtjevu 8, naznačena time što je vrijeme infuzije za intravenoznu injekciju 1-2 sata za navedenu efikasnu terapeutsku količinu PLD i oko 3 sata za navedenu efikasnu terapeutsku količinu ET-743.
The cargo trailer with the mechanism for moving wheel axles according to any of the preceding claims, characterized in that the chassis (1) is made of a one-shaft, two-shaft or more-shaft frame, preferably of a two-shaft frame, wherein the shaft of the frame may have any shape, preferably the shape of a tube. 
Å umarska traktorska prikolica s mehanizmom za premještanje osovina kotača prema bilo kojem od prethodnih zahtjeva, naznačena time, da je šasija (1) načinjena kao jednoosovinski, dvoosovinski ili višeosovinski nosivi okvir, poželjno kao dvoosovinski okvir, pri čemu osovina okvira može imati bilo koji oblik, a poželjno je u obliku cijevi.
Method for making an ankle sock (10) according to claim 2 characterised in that said at least one other yarn-feeder suitable for embroidering, can embroider with different coloured yarns to those used by said at least one yarn-feeder suitable for stitching. 
Postupak proizvodnje nazuvka za gležanj (10) u skladu s patentnim zahtjevima 2, naznačen time što navedeni najmanje jedan drugi dodavač niti pogodan za vezenje, može praviti vez s nitima obojenim drugačije u odnosu na one koje se upotrebljava s navedenog najmanje jednog dodavača niti pogodnog za šivanje.
the amount of resources for the ACK or the NACK is calculated based on the resource allocation information. The communication method of claim 13, wherein the amount of resources for the ACK or the NACK does not exceed a predetermined amount. 
Komunikacijski postupak prema zahtjevu 14, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi unaprijed određenu količinu.
The composition according to claim 1, wherein the ACE inhibitor is tert-butylamine or arginine salt of perindopril, or ramipril in the form of free acid. 
Pripravak prema zahtjevu 1, naznačen time da ACE inhibitor je tert-butilamin ili argininska sol perindoprila, ili ramiprila u obliku slobodne kiseline.
A composition comprising at least one isolated IL-23p19 antibody to any of claims 1-4 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Sastav koji obuhvaća najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i najmanje jedan farmaceutski prihvatljiv nosač ili razblaživač, opcionalno dodatno obuhvaćajući najmanje jedan spoj ili polipeptid izabran od detektabilne oznake, ili reportera, TNF antagonista, anti infektivnog lijeka, lijeka kardiovaskularnog (CV) sustavaa, lijeka centralnog nervnog sustava (CNS), lijeka autonomnog nervnog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog (GI) trakta, hormonalnog lijeka, lijeka za ravnotežu tekućine ili elektrolita, hematološkog lijeka, aneoplastičnog, imunomodulacijskog lijeka, oftalmičkog, ušnog ili nazalnog lijeka, topikalnog lijeka, nutricijskog lijeka, citokina i citokin antagonista.
Filtering the flow suctioned by the mobile suction means, with at least one filtration means; and 
najmanje jedno sredstvo za filtriranje (3) koje filtrira strujanje vode koja sadrži nataložene čestice;
A method of coating a substrate according to any preceding claim, wherein the total dry film thickness of the primer anti-corrosive coat (a) (i) is typically 30-500µm. 
Metoda premazivanja supstrata sukladno bilo kojem ranijem zahtjevu, naznačena time što ukupna debljina suhog filma temeljnog antikorozivnog premaza (a) (i) iznosi uobičajeno 30 - 500 um.
for use in treating a cancer which has a defect in ATM signaling pathway. 
za upotrebu u liječenju tumora kod pacijenta.
represents a halogen atom or a hydrogen atom; and R7 represents a halogen atom. 
R*predstavlja atom vodika; i R' predstavlja atom halogena.
The method according to claim 12, wherein step iii) is performed by gently adding the oil phase provided in step i) to the suspension provided in step ii). 
Postupak u skladu s patentnim zahtjevom 12, gdje korak iii) se provodi opreznim dodavanjem uljne faze dodane u koraku 1) u suspenziju dodanu u koraku ii), t>&
In contrast, there was a statistically significant drug effect on the flicker, the fusion and the flicker-fusion thresholds (CFF) that were higher after administration of single 60 mg 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride than after administration of placebo. These results indicate that single oral administration of 60 mg of the product increased the subject's vigilance. 
Nasuprot tome, postoji statistički značajan učinak lijeka na prag za,,Flicker" 1 prag za,,Flicker-fusion". (CFF) koji su bili viši nakon primjene jednokratne doze od 60 mg 1-[3-[3-(4-klorfenil)propoksilpropil|-piperidin monoklorida nego kod primjene placeba. Ovi rezultati pokazuju da jednokratna oralna primjena od 60 mg proizvoda povećava pažnju kod subjekata.
A GLYX peptide for use as in claim 12, wherein the treatment-resistant patient is identified as one who is unwilling or unable to tolerate a side effect of at least one type of antidepressant treatment. 
GLYX-13 za primjenu u skladu sa zahtjevom 5, naznačeno time da je pacijent rezistentan na terapiju pacijent koji ne želi ili ne može tolerirati sporedne efekte najmanje jednog tipa antidepresivnog tretmana.
Use according to claim 1 characterized in that the active ingredients are presented in fixed or free combination for simultaneous, sequential or separate administration together with the usual excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da su nazočne djelatne tvari u fiksiranoj ili slobodnoj kombinaciji za istovremenu, serijsku ili posebnu primjenu zajedno s uobičajenim ekscipijensima, dodacima i aditivima u farmaceutskom obliku prikladnom za primjenu putem inhalacije.
The compound according to claim 53 which is selected from the group consisting of: 3-methyl-N-(propylidene)-1H-indol-1-amine; 
. Spoj prema patentnom zahtjevu 53 koji se bira iz skupine koja se sastoji od: 3-metil-N-(propiliden)-1H-indol-1-amin;
The filtrate was evaporated to get solids, isolated the solids in methanol (38 ml) at 0-5° C. The solid was dried to get 4.0 g of nebivolol base. 
Filtrat je isparen da bi se dobile krute tvari, koje su izolirane u metanolu (38 ml) na 0-5 *C. Kruta tvar je osušena da bi se dobilo 4,0 g nebivolol baze.
To a solution of the intermediate from step, B (1.64 g, 5.25 mmol) in dichloromethane (20 mL) was added trifluroacetic acid (20 mL) and the resulting solution stirred at room temperature for 4 hours. 
U otopinu intermedijera iz koraka B (1.64 g, 5.25 mmol) u diklorometanu (20 mL) doda se trifluorooctena kiselina (20 mL) i rezultirajuća otopina se miješa na sobnoj temperaturi tijekom 4 sata.
The tablet or tablet layer of claim 1 comprising sorbitol having a D(0.5) average particle size of 100-350µm, preferably 120-300µm and most preferably 150-200µm. 
Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da sadrže sorbitol koji ima D (0.5) prosječne veličine veličine čestica od 100-350 um, povoljnije je 120-300 um i najpovoljnije je od 150-200 um.
The liquefied gas treatment system according to claim 2, wherein a gas component in the third stream decompressed to a gas-liquid mixed state is joined with the first stream of the boil-off gas discharged from the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
The process of embodiment 22, wherein the salt of formula (IVB) is converted to the compound of formula (IVA) in free base. 
Postupak prema patentnom zahtjevu 8, naznačen time, što se sol formule (IVB) pretvara u spoj formule (IVA) u slobodnoj bazi.
wherein a modifiable coefficient is a coefficient between a first non-zero coefficient according to a reverse scan order of the residual block and a last non-zero coefficient according to the reverse scan order, inclusive of the first and the last non-zero coefficients, wherein the count of modifiable coefficients in the set of coefficients is greater than 4, and 
ako je navedeni broj ne-nula koeficijenata veći od ili jednak pet, znak a prvi ne-nula koeficijent je skriven, a paritet zbroja navedenih barem pet ne-nula koeficijenata označava vrijednost navedenog skrivenog znaka, te
The CO2 absorbent according to claim 1, wherein the concentration of AMP is from 10 to 35 % by weight and the concentration of AP or AB is from 10 to 40% by weight. 
Vodeni apsorbens CO2 prema zahtjevu 1, naznačen time da je koncentracija AMP s masenim udjelom od 10 do 35 i da je koncentracija AP ili AB s masenim udjelom od 10 do 40%.
The reading of the voltage at pin A0 is carried out in the same way as the reading of the output 90u voltage of amplifier 90: the absolute value of the difference between the voltage at pin A0 and the zero-voltage (stored as zero-value during the above described phase IV) is compared with a limit-value stored in the ROM of unit 50 and, if greater, relay 20 is tripped thereby disconnecting the load 16. 
Očitavanje napona na pinu A0 se odvija na jednak način kao očitavanje izlaznog napona 90u pojačala 90: apsolutna vrijednost razlike napona na pinu AQ i nultog napona (spremljenog kao nulta vrijednost za vrijeme prije opisane faze IV) se uspoređuje s graničnom vrijednosti spremljenoj u ROM-u jedinice 50 i, ako je veća, relej 20 se okida i tako odspaja trošilo 16.
The extended release tablet formulation according to claim 1, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da rezultirajuća tableta osigurava pH-ovisno oslobađanje karakterizirano bržim oslobađanjem karakterističnim u rasponu pH < 4.5, te sporijim i nadalje pH-neovisnim oslobađanjem karakterističnim u rasponu od pH 4.5 do 7.5.
A compound of Formula I or II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein: 
Spoj s Formulom II: [image] ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol, naznačen time da: A je CONHOH;
A method for determining whether an agent reduces IL-15 mediated lymphocyte infiltration of a tissue or joint comprising measuring lymphocyte infiltration of the tissue or the joint at one or time points following administration of the agent to a genetically modified rodent as defined in claim 1 or 2 over a period of time, and determining whether the agent reduces lymphocyte infiltration of the tissue or joint. 
mjerenju infiltriranja limfocita u tkivo ili zglob u jednoj ili više vremenskih točaka nakon primjene sredstva na genetički modificiranom glodavcu u skladu s patentnim zahtjevom 1 ili 2 u određenom vremenskom periodu, i određivanju smanjuje li sredstvo infiltriranje limfocita u tkivo ili zglob.
The method of claim 8 wherein the GlyT1 inhibitor is selected from the group consisting of: 
GlytI inhibitor za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je GlyT1 inhibitor odabran od
The artificial T cell receptor of any one of items 17 to 24, wherein the binding domain for CLDN6 comprises an amino acid sequence represented by SEQ ID NO: 40 or a fragment thereof, or a variant of said amino acid sequence or fragment. 
Umjetni T stanični receptor sukladno patentnom zahtjevu 6 ili 7, naznačen time da vezivna domena za CLDN6 sadrži aminokiselinsku sekvencu predstavljenu pomoću SEK ID BR: 40.
In some aspects, provided herein are computer systems that can be used to determine if a subject is likely to have or be at risk of chronic kidney disease or proteinuria. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je namijenjen upotrebi u liječenju subjekta koji ima ili je u opasnosti od kronične bubrežne bolesti ili proteinurije.
is a single bond when R2 is H, or 
je jednostruka veza kada Roje H, ili